Key points are not available for this paper at this time.
Serotonin (5-hydroxytryptamine; 0.5 microM and above) stimulated the synthesis of prostacyclin (as measured by radioimmunoassay of 6-ketoprostaglandin F1 alpha) by bovine aortic smooth muscle cells in culture. This effect was structurally specific; a similar response was not elicited by the other indoles (tryptophan, n-acetylserotonin, 5-hydroxytryptophan, melatonin, or 5-hydroxyindoleacetic acid) or by the amines phenylephrine, isoproterenol, dopamine, or histamine). The response was reversible and was saturable at serotonin concentrations of 10 microM or higher. An increase in prostacyclin synthesis was elicited by the addition of a serotonin agonist, quipazine (1 microM and above), and antagonized by the serotonin receptor blockers cyproheptadine, methysergide, or methiothepin but not by other aminergic receptor-blocking drugs (e.g., phentolamine or propranolol). This effect was selective for cell type because serotonin or quipazine (100 microM) did not increase prostacyclin synthesis by bovine aortic endothelial cells. The addition of platelet-derived growth factor (PDGF) to cultures of smooth muscle cells dramatically enhanced prostacyclin synthesis in response to the coadministration of serotonin. PDGF greatly increased the maximum response to serotonin without altering the half-maximal effective concentration for serotonin. This synergistic interaction was blocked by the addition of a serotonin-receptor blocking agent. Taken together, these data suggest that serotonin stimulates smooth muscle prostacyclin synthesis through a specific receptor-mediated mechanism that can be modulated by PDGF.
Coughlin et al. (Sun,) studied this question.